CDC - African Trypanosomiasis ShareCompartir African Trypanosomiasis, also known as "sleeping sickness," is caused by microscopic parasites of the species Trypanosoma brucei. It is transmitted by the tsetse fly (Glossina species), which is found only in rural Africa. Although the infection is not found in the United States, historically, it has been a serious public health problem in some regions of sub-Saharan Africa. Currently, about 10,000 new cases each year are reported to the World Health organization; however, it is believed that many cases go undiagnosed and unreported. Sleeping sickness is curable with medication, but is fatal if left untreated. Image: L&R: Trypanosoma bruceissp. in thin blood smears stained with Giemsa. Center: A close up of a tsetse fly. Credit: DPDx The history of African trypanosomiasis | Parasites & Vectors | Full Text The history of African trypanosomiasis © Steverding; licensee BioMed Central Ltd.

2008 Received: 13 December 2007 Published: 12 February 2008 Abstract The prehistory of African trypanosomiasis indicates that the disease may have been an important selective factor in the evolution of hominids. Ancient history and medieval history reveal that African trypanosomiasis affected the lives of people living in sub-Saharan African at all times. Modern history of African trypanosomiasis revolves around the identification of the causative agents and the mode of transmission of the infection, and the development of drugs for treatment and methods for control of the disease. From the recent history of sleeping sickness we can learn that the disease can be controlled but probably not be eradicated. Current history of human African trypanosomiasis has shown that the production of anti-sleeping sickness drugs is not always guaranteed, and therefore, new, better and cheaper drugs are urgently required. Background African trypanosomiasis is an infectious disease of humans and animals of similar aetiology and epidemiology.

The causative agents of the disease are protozoan parasites of the genus Trypanosoma that live and multiply extracellularly in blood and tissue fluids of their mammalian hosts and are transmitted by the bite of infected tsetse flies (Glossina sp.). The distribution of trypanosomaisis in Africa corresponds to the range of tsetse flies and comprises currently an area of 8 million km2 between 14 degrees North and 20 degrees South latitude [ 1 ]. Throughout history, African trypanosomiasis has severely repressed the economic and cultural development of Central Africa. African animal trypanosomiasis or nagana disease is caused by T. congolense, T. vivax and T. brucei spp. In wild animals, these parasites cause relatively mild infections while in domestic animals they cause a severe, often fatal disease. All domestic animals can be affected by nagana and the symptoms are fever, listlessness, emaciation, hair loss, discharge from the eyes, oedema, anaemia, and paralysis.

As the illness progresses the animals weaken more and more and eventually become unfit for work, hence the name of the disease "N'gana" which is a Zulu word that means "powerless/useless" [ 2 ]. Because of nagana, stock farming is very difficult within the tsetse belt. Human African trypanosomiasis or sleeping sickness is caused by two subspecies of T. brucei, T. brucei gambiense and T. brucei rhodesiense, while the third subspecies, T. brucei brucei, is only infectious to animals. T. b. gambiense is responsible for the chronic form of sleeping sickness in West and Central Africa, whereas T. b. rhodesiense gives rise to the acute form of the disease in East and Southern Africa. There are two distinct stages during the course of sleeping sickness. The first or early stage of the disease, also known as the haemolymphatic phase, is defined by the restriction of the trypanosomes to the blood and lymph system [ 3 ]. The symptoms of this stage are fever, headaches, joint pains and itching.

The second or late stage of the disease, also known as the neurological phase, is characterised by the presence of the parasites in the cerebrospinal fluid [ 3 ]. In general, this is when the typical signs of the disease occur: confusion, disturbed sleep pattern, sensory disturbances, extreme lethargy, poor condition and coma. If left untreated, sleeping sickness patients die within months when infected with T. b. rhodesiense or within years when infected with T. b. gambiense. Wild and domestic animals may play a major role as parasite reservoirs for human infections with trypanosomes [ 3 – 5 ]. Prehistory Phylogenetic reconstruction based on the genes coding for the small subunit ribosomal RNA suggested that all Salivarian trypanosomes (to which African trypanosomes belong) separated from other trypanosomes approximately 300 million years ago [ 6 ]. Probably soon after their emergence, Salivarian trypanosomes became gut parasites or commensals of early insects, which evolved around 380 million years ago. With the appearance of tsetse flies some 35 million years ago, trypanosomes have been transmitted to mammals by these bloodsucking insects.

The long coexistence of both tsetse flies and game animals may explain why most African wildlife species are tolerant of trypanosomiasis: they become infected by the parasite but show no ill effects [ 7 ]. In contrast, domestic animals have yet been unable to develop tolerance or resistance to trypanosome infections within the 13000 years of their breeding. It is likely that trypanosomiasis has played an important role in early hominid evolution. Probably, the disease had an important role in the selection of trypanosome-resistant early terrestrial hominids. This is evident from the observation that arboreal primates are susceptible to trypanosomiasis while humans, with the exception of T. b. gambiense and T. b. rhodesiense infections, are resistant [ 7 ]. The fact that humans are resistant to all other African trypanosome species indicates that human African trypanosomiasis is a recent event in human development. Presumably the sustained transmission of trypanosomes between tsetse flies and humans in West Africa has led to the evolution of the less virulent T. b. gambiense subspecies [ 7 ]. In contrast, the T. b.

rhodesiense subspecies has remained ill-adapted to humans and is transmitted from game animals to humans [ 7 ]. The infectivity of T. b. rhodesiense to humans is due to a serum-resistant-associated (SRA) gene [ 8 ]. It seems that the SRA gene originated in a single event and then spread through T. brucei in East Africa by genetic exchange [ 9 ]. Antiquity It is well established that in ancient times the north coast of the African continent held more lush vegetation than today [ 10 ]. Also the flora and fauna of the Nile valley during the Old Kingdom (3000 BC – 2000 BC) was quite different and probably similar to the current region of the Gazelle River (one of the major tributaries of the Nile River) in Sudan [ 2 ]. The distribution of tsetse flies should therefore have extended much more northwards and ranged into the Nile delta. Hence, it is reasonable to assume that shepherds and livestock breeders in these regions experienced the problem of trypanosomiasis. This is also evident from the fact that the Egyptians of the Old Kingdom kept their cattle together with game animals [ 2 ].

The ancient Egyptians did this not because they were inexperienced in breeding but could only successfully rear trypanotolerant animals. Further evidence for the presence of trypanosomiasis in ancient Egypt comes from the Veterinary Papyrus of the Kahun Papyri dating from 2nd millennium BC [ 11 ] in which a cattle disease is described that resembles nagana (Fig. 1 ). It seems that an ointment made from the fat of particular birds was used as treatment against the bite of flies [ 12 ]. During the course of the Middle Kingdom (2000 BC – 1300 BC) the stream course of the Nile River was adjusted and thus the breeding sites of tsetse flies were largely destroyed. At that time the Egyptians gave up raising game animals and discontinued growing pure breeds of the trypanotolerant aurochs (Bos primigenius). Instead, they interbred the aurochs with the more efficient Indian zebu cattle (Bos indicus) [ 2 ]. The gradual eradication of the tsetse fly due to the progressing regulation of the Nile River eventually allowed the ancient Egyptians to raise pure breeds of zebu cattle [ 2 ].

In addition, it is told that the horse, which was not introduced until the 16th century BC, was also difficult to breed in ancient Egypt [ 2 ]. It is probable that failure in horse breeding was also due to trypanosome infections by tsetse flies. Figure 1 Last section of the damaged Veterinary Papyrus of the Kahun Papyri about the cattle disease ushau dating from 2 nd millennium BC. The translation reads as follows: (1) Title: Treatment of the eyes (?) of a bull with ushau in winter. (2) If you see a bull with ushau (3) in winter, and he is blinded (?), (4) his two eyes are thick; gash thou as (5) above. If you see a bull (6) with ushau in winter from cold, (7) since its arrival in (?) the summer, (8) his temples are wrinkled (?), his eyes are running, his stomach groaning (?), (9) he does not walk (?) .........(10) ............... (11) ............... (12) thou all his body with .........

as is done to one (13) with a bruise (?) [11]. Middle Ages There are only a few written reports giving evidence for the occurrence of trypanosomiasis in Africa during the Middle Ages. Most of these reports are from the Arabs who kept close trade relations with the West African kingdoms such as Benin, Ghana, Mali and Songhai. One of the first historical records on human trypanosomiasis is by the famous Arabian geographer Abu Abdallah Yaqut (1179–1229). During his journey into Africa he found in the "Country of Gold" (Wangara [ 13 ]) an underground village whose inhabitants and even their dogs were just skin and bones and asleep [ 2 ]. This scene is reminiscent of the devastating sleeping sickness epidemic in Uganda at the turn of the 20th century. A first case report of sleeping sickness comes from the Arabian historian Ibn Khaldun (1332–1406).

In his historical work he reported that a fellow countryman told him about the death of the Sultan Mari Jata, Emperor of Mali, who died of an illness which, according to the description, corresponds to human trypanosomiasis [ 14 ]: "He told me that Jata had been smitten by the sleeping illness, a disease which frequently afflicts the inhabitants of that climate, especially the chieftains who are habitually affected by sleep. Those afflicted are virtually never awake or alert. The sickness harms the patient and continues until he perishes. He said that the illness persisted in Jata's humour for a duration of two years after which he died in the year 775 AM (= 1373/74 in our calendar)." A striking example of the impact of trypanosomiasis on the life and destiny of people is the eastward migration of the Fulbe (Fulani) in the northern parts of West Africa [ 2 ]. It is believed that in ancient times the Fulbe people have moved from Egypt or Ethiopia to the area of present-day Senegal.

At the beginning of the 13th century when the Sahara was getting increasingly dryer, they were forced to relocate southwesterly into the savannah area. As cattle-breeding was their economic basis, the Fulbe did not risk continuing their migration southward otherwise they would have entered the tsetse belt and lost their herds. Hence, they moved eastward and settled south of the Sahara but north of the tsetse belt in regions with sufficient grazing land. Modern Times Early Modern Times In early Modern Times, the history of human African trypanosomiasis is closely linked to the slave trade. First accounts of sleeping sickness came from ship doctors and medical officers who worked for slave-trade companies. As sleeping sickness caused increasing losses, ship-owners and slave-traders pressed their ship doctors to investigate this eerie disease. In 1734, the English naval surgeon John Aktins (1685–1757) published the first accurate medical report on African sleeping sickness [ 15 ].

However, whereas Aktins described only the neurological symptoms of the late stage of sleeping sickness, the English physician Thomas Winterbottom (1766–1859) published in 1803 a report referring to the characteristic sign of swollen lymph glands along the back of the neck in the early stage of the disease [ 15 ]. He also mentioned that this symptom was known long ago by Arabian slave-traders who refrained from buying slaves with this sign [ 2 ]. Although throughout the 19th century, reports on sleeping sickness increased and human African trypanosomiasis became a well-recognised disease, no one had any real idea about the nature of the illness [ 15 ]. Discovery of the tsetse fly-trypanosome complex It was the Scottish missionary and explorer David Livingston (1813–1875) who first suggested that nagana is caused by the bite of tsetse flies.

In 1852, he reported the occurrence of a disease in the valleys of the Limpopo and Zambezi rivers as well as at the banks of the lakes Nyasa and Tanganyika from which all the cattle he carried died after they have been bitten by tsetse flies [ 2 ]. However, it took another 40–50 years until trypanosomes were identified as the causative agents of nagana and sleeping sickness. In 1895, the Scottish pathologist and microbiologist David Bruce (1855–1931) (Fig. 2 ) discovered T. brucei as the cause of cattle trypanosomiasis (cattle nagana) [ 16 ]. The first unequivocal observation of trypanosomes in human blood was made by the British Colonial surgeon Robert Michael Forde (1861–1948) in 1901 when he examined a steamboat captain in The Gambia [ 17 ].

He first thought that the organisms he found were worms [ 15 ] but the English physician Joseph Everett Dutton (1874–1905) identified them as trypanosomes a few months later and proposed in 1902 the species name Trypanosoma gambiense (now T. b. gambiense) [ 18 ]. In the same year, the Italian physician and pathologist Aldo Castellani (1878–1971) found trypanosomes in the cerebrospinal fluid of sleeping sickness patients and suggested that they cause sleeping sickness [ 15 , 19 ]. One year later, Bruce provided conclusive evidence that sleeping sickness is transmitted by tsetse flies [ 15 , 20 ]. At that time, however, he believed that trypanosomes were transmitted mechanically by tsetse flies [ 15 ]. It was the German military surgeon Friedrich Karl Kleine (1869–1951) who showed in 1909 the cyclical transmission of T. brucei in tsetse flies [ 21 ].

This prompted Bruce to change his original opinion of mechanical transmission of trypanosomes, and instead describe the full developmental cycle of the parasites within their insect host [ 15 ]. In the meantime, the two other animal pathogenic trypanosome species T. congolense and T. vivax were discovered in 1904 and 1905 by the Belgian physician Alphonse Broden (1875–1929) [ 22 ] and the German naval doctor Hans Ziemann (1865–1905) [ 23 ], respectively. The second human pathogenic trypanosome species, T. rhodesiense (now T. b. rhodesiense), was eventually recovered in 1910 by the parasitologists John William Watson Stephens (1865–1946) and Harold Benjamin Fantham (1876–1937) [ 24 ]. Figure 2 Sir David Bruce (1855–1931). The Scottish bacteriologist identified T. brucei as the aetiological agent of nagana disease.

Epidemics and control of the disease In the 20th century, Africa saw three severe sleeping sickness epidemics. The first one began in 1896 and lasted until 1906, and affected mainly Uganda and Congo [ 3 ]. It was a devastating epidemic with 300,000 and 500,000 people estimated to have died in the Congo Basin and the Busoga focus in Uganda and Kenya, respectively [ 20 , 25 ]. The disastrous effects of the epidemic worried the colonial administrations to such an extent that they sent out scientific missions to investigate the disease (see above) and to develop a cure [ 2 , 20 ]. The French physician Charles Louis Alphonse Laveran (1845–1922) and the French biologist Félix Mesnil (1868–1938) were the first to report in 1902 that sodium arsenite was effective in infected laboratory animals [ 15 ].

In 1904, a paper was published by the Canadian doctor Harold Wolferstan Thomas (1875–1931), and the Austrian doctor and zoologist Anton Breinl (1880–1944), informing that the arsenical drug atoxyl could cure experimentally infected animals [ 2 ]. It was thought to be better than any other arsenical compound tested so far and relatively atoxic (hence the name) [ 2 ]. However, the German physician Robert Koch (1843–1910), who investigated the trypanocidal activity of atoxyl on sleeping sickness patients on the Ssese Islands located in the northwest of Lake Victoria, found that the drug was by no means nontoxic; of 1622 atoxyl-treated patients Koch observed 22 cases of atrophy of the optic nerve with complete blindness [ 2 ]. In 1907, Koch informed the German scientist Paul Ehrlich (1854–1915) about these complications and advised him to improve the drug atoxyl [ 2 ].

Already in 1904 Ehrlich had become interested in the chemotherapy of trypanosomiasis and had developed the dye trypan red, which proved to be both curative and prophylactic for T. equinum (a species of trypanosomes that causes Mal de Caderas in horses in Central and South America) in mice but not for T. brucei [ 26 ]. Eventually, it was Ehrlich's former assistant Wilhelm Roehl (1881–1929) who in 1916, with the help of a small team of chemists and the German chemical and pharmaceutical company Bayer, developed the first effective drug for treatment of sleeping sickness. The compound, Bayer 205, (later named suramin) is still in use in the therapy of early-stage T. b. rhodesiense infections [ 2 ]. A year earlier, the American chemist Walter A. Jacobs (1883–1967) and the American immunologist Michael Heidelberger (1888–1991) discovered the organo-arsenical tryparsamide.

This was the first drug to treat late-stage sleeping sickness alone, or in combination with suramin, and was also employed in the treatment of animal trypanosomiasis [ 26 ]. Both drugs helped to fight the second major sleeping sickness epidemic which began in a number of African countries in 1920 and died down by the late 1940s (Fig. 3 ) [ 3 , 27 ]. Another important measure towards the control of the 1920s sleeping sickness epidemic was the introduction of mobile teams [ 20 ]. This method of systematic case detection and treatment with the aim of elimination of the parasite reservoir was suggested by the French military surgeon Eugène Jamot (1879–1937). In 1926, after long opposition by his superiors in Paris, Jamot was allowed to set up a special service in Cameroon that showed the effectiveness of his approach; within 11 years the prevalence levels of sleeping sickness declined from 60% in 1919 to 0.2–4.1% in 1930 [ 20 ]. Subsequently, other colonial powers introduced the method of mobile teams for T. b.

gambiense sleeping sickness control [ 20 ]. Other approaches to the control of African trypanosomiasis were vector control, host reservoir control and game destruction [ 20 ]. Vector control was already introduced in 1910 and included the use of differently designed traps and bush clearing. Between 1920 and 1940, reservoir host control and game destruction, which was practised mainly in East Africa on the recommendation of Bruce, resulted in a significant reduction, but never in the extermination, of the tsetse fly population [ 20 ]. A third drug for treatment of the early stage of T. b. gambiense sleeping sickness, pentamidine, was developed by the English chemist Arthur James Ewins (1882–1958) of the pharmaceutical company May and Baker in 1937 [ 28 ]. With the discovery of its insecticidal properties in 1939, DDT was used by 1949 in the hope of freeing large parts of endemic areas from tsetse flies [ 2 , 20 ].

Also in 1949, the arsenical melarsoprol, which was developed by the Swiss pathologist, microbiologist and chemist Ernst Friedheim (1899–1989), was introduced for the treatment of late stage human African trypanosomiasis. It was the first and is still the only effective drug for late stage T. b. rhodesiense sleeping sickness. Since the 1950s, several drugs have become available for chemotherapy of animal trypanosomiasis. These include the phenanthridine derivatives homidium bromide (Ethidium®, Novidium®) and isometamidium chloride (Samorin®, Trypamidium®), the aminoquinaldine derivative quinapyramine (Anthrycid®) and the aromatic diamidine diminazene aceturate (Berenil®) [ 29 ]. Eventually, the combined employment of chemotherapy, systematic case detection and vector control led to a dramatic reduction in the incidence of sleeping sickness at the beginning of the 1960s (Fig. 3 ) [ 27 ].

Figure 3 Number of reported cases of sleeping sickness and population screened, 1939–2004. Grey columns, number of reported cases; black circles, population screened. Data derived from [27,33]. Other factors that affected the epidemiology of sleeping sickness in the first half of the last century are the socio-economic conditions created during the colonisation of Africa. An excellent example of this is the sleeping sickness epidemic in the north-central Uele district of the former Belgian Congo, now known as the Democratic Republic of Congo [ 30 ]. Colonisation of this region in the first decade of the 19th century was protracted and brutal. Large numbers of people were displaced and many of them experienced famine. This created an ideal environment for spreading the disease and sleeping sickness became increasingly entrenched and epidemic in this region over the next 15 years. It was not until the mid 1920s that medical services were introduced in the Uele district by the colonial powers. Five years later, the epidemic was under control due, as claimed by the Belgian authorities, to the medical interventions.

However, improvements in nutrition and hygiene are likely to have had as much to do with the decline of sleeping sickness as the medical interventions [ 30 ]. By the 1930s, many people in Belgian Congo no longer suffered from intense social and economic disruption and learned how to better cope with the rules and controls of the colonial powers while the Belgians at the same time ceased their social engineering practice of abrupt resiting of whole communities [ 30 ]. By the mid 1960s, most of the trypanosomiasis-endemic countries became independent and were no longer supported by their former colonial powers. In the aftermath of decolonisation, many African countries experienced political instability and economic ruin with a disastrous effect on the health services. After a decade of low endemicity, the control of trypanosomiasis was no longer a priority. As a consequence, control programmes were stopped and population screening declined to very small numbers of people (Fig. 3 ) [ 27 ]. Concerns about the environmental effect of DDT led to a ban of the insecticide in disease vector control worldwide in the 1970s.

The result of all this was that since the mid 1970s there has been a steady increase in the number of reported sleeping sickness cases (Fig. 3 ) [ 27 ]. This was the beginning of the third and most recent sleeping sickness epidemic in the 20th century, mainly affecting Angola, Congo, Southern Sudan and the West Nile district of Uganda [ 3 , 20 ]. The situation remained unchanged until 1990 when eflornithine (DL-α-difluoromethylornithine, DFMO), a selective inhibitor of ornithine decarboxylase, was introduced for treatment of late stage T. b. gambiense sleeping sickness. Eflornithine was initially developed by scientists at the Merrell Research Institute in Strasbourg for treatment of cancer [ 31 ], but was then found to be an effective therapeutic agent against T. b. gambiense. Although the administration regime is strict and difficult, eflornithine was a welcome alternative to melarsoprol treatment as it is less toxic.

Recent developments and current situation At the turn of the millennium, the scale of sleeping sickness had almost reached, yet again, the levels of the epidemics seen at the beginning of the century (Fig. 3 ) [ 27 , 32 ]. The situation got even worse as the production of eflornithine was ceased and that of melarsoprol was threatened to be discontinued. Fortunately, in 2001 the World Health Organization (WHO) reached an agreement with the pharmaceutical companies Aventis (now Sanofi-Aventis) and Bayer AG to provide sleeping sickness drugs free of charge for endemic countries [ 3 , 32 ]. The aid organisation Médicins Sans Frontières was commissioned with the distribution of the drugs. By 1997, surveillance had been reinforced and since 1998 the number of new cases has dropped steadily (Fig. 3 ) [ 33 ]. At present, the estimated number of infected patients is thought to be between 50,000 and 70,000 [ 3 ].

In 2001, the Organisation of African Unity (OAU) launched a new initiative, the Pan African Tsetse and Trypanosomiasis Eradication Campaign (PATTEC) to eliminate the tsetse fly from Africa [ 34 ]. It was planned to employ an area-wide approach using odour-baited traps, insecticide-treated targets and pour-ons and ultra-low volume aerial spraying of insecticides to reduce the tsetse fly population, and finally the sterile male technique to ensure total elimination of the target Glossina species [ 34 ]. The sterile male technique was successfully used in the eradication of tsetse flies and thus trypanosomiasis on the island of Zanzibar in 1997 [ 35 ]. However, in contrast to the Zanzibar project, which worked because it was on an island (isolated area of 1,651 km2) infested with only one tsetse fly species, the PATTEC initiative has to deal with a vast area of sub-Saharan Africa (~10 million km2) inhabited by at least 7 different Glossina species recognised as vectors for transmission of sleeping sickness.

Therefore, many scientists are sceptical that the PATTEC project will succeed as similar eradication campaigns failed in the past because the tsetse fly infested areas could not be isolated [ 36 ]. The huge costs associated with the eradication project are also a concern as most of the countries involved belong to the most heavily indebted poor countries in the world [ 36 ]. The only new drug candidate currently in development for treatment of sleeping sickness is the diamidine pafuramidine (DB289). In January 2007, pafuramidine had completed enrolment for Phase III clinical trials in the Democratic Republic of Congo and Angola [ 37 , 38 ] which is the final step before the compound can be registered as a drug against human African trypanosomiasis. If successful, pafuramidine would be the first orally available treatment for early stage sleeping sickness. Another approach to improve the treatment of sleeping sickness is the development of a combination therapy. Currently, the anti-Chagas disease drug, nifurtimox, is being tested in combination with melarsoprol or eflornithine in a randomized clinical trial in Uganda [ 39 , 40 ].

There is also an urgent need for accurate tools for the diagnosis of human African trypanosomiasis. The existing tests for diagnosis are not sensitive and specific enough, due to the characteristically low number of parasites found in the blood of sleeping sickness patients. Therefore, the Foundation for Innovative New Diagnostics (FIND) and the WHO launched, in 2006, a new initiative for the development of new diagnostic tests to support the control of sleeping sickness [ 41 ]. It is expected that the new test will allow for early case detection and simplified staging and, thus, will improve disease management and support for the elimination of sleeping sickness as a public health problem. Conclusion The history of African trypanosomiasis gives an example of how a disease not only affected the evolution of humans but also the cultural and economic development of people in sub-Saharan regions. From the historical events of the 20th century one can learn that a concerted approach of systematic case detection and treatment is the appropriate method for the control of sleeping sickness and that discontinuation of these control measures will lead to re-emergence and spread of the disease. History has also shown that African trypanosomiasis always prevented the introduction of stock farming in endemic areas.

A consequence of this is that much of tropical Africa is still present today and has not been converted into grassland for cattle breeding. Declarations Acknowledgements I thank Drs Orla Jupp and Darren Sexton for critical reading of the manuscript and the London School of Hygiene & Tropical Medicine for providing the image of Sir David Bruce and the permission to use it. Authors' original submitted files for images Below are the links to the authors’ original submitted files for images. 13071_2007_3_MOESM1_ESM.pdf Authors’ original file for figure 1 13071_2007_3_MOESM2_ESM.pdf Authors’ original file for figure 2 13071_2007_3_MOESM3_ESM.pdf Authors’ original file for figure 3 Competing interests The author declares that he has no competing interests. Authors’ Affiliations BioMedical Research Centre, School of Medicine, Health Policy and Practice, University of East Anglia References Molyneux DH, Pentreath V, Doua F: African trypanosomiasis in man. Manson's Tropical Diseases. Edited by: Cook GC.

1996, London: W.B. Saunders Company Ltd, 1171-1196. 20 Google Scholar Winkle S: Geißeln der Menschheit. Kulturgeschichte der Seuchen. 2005, Düsseldorf: Artemis & Winkler Google Scholar World Health Organization: African trypanosomiasis (sleeping sickness). 2006, World Health Organ Fact Sheet, [ ] Google Scholar Njiokou F, Laveissière C, Simo G, Nkinin S, Grébaut P, Cuny G, Herder S: Wild fauna as a probable animal reservoir for Trypanosoma brucei gambiense in Cameroon. Infect Genet Evol. 2006, 6: 147-153. 10.1016/j.meegid.2005.04.003.

View Article PubMed Google Scholar Simo G, Asonganyi T, Nkinin SW, Njiokou F, Herder S: High prevalence of Trypanosoma brucei gambiense group 1 in pigs from the Fontem sleeping sickness focus in Cameroon. Vet Parasitol. 2006, 139: 57-66. 10.1016/j.vetpar.2006.02.026. View Article PubMed Google Scholar Haag J, O'hUigin C, Overath P: The molecular phylogeny of trypanosomes: evidence for an early divergence of the Salivaria. Mol Biochem Parasitol. 1998, 91: 37-49. 10.1016/S0166-6851(97)00185-0. View Article PubMed Google Scholar Lambrecht FL: Trypanosomes and hominid evolution. Bioscience. 1985, 35: 640-646. 10.2307/1309990.

View Article Google Scholar De Greef C, Imberechts H, Matthyssens G, Van Meirvenne N, Hamers R: A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense. Mol Biochem Parasitol. 1989, 36: 169-176. 10.1016/0166-6851(89)90189-8. View Article PubMed Google Scholar Gibson WC: The SRA gene: the key to understand the nature of Trypanosoma brucei rhodesiense. Parasitology. 2005, 131: 143-150. 10.1017/S0031182005007560.

View Article PubMed Google Scholar Jolly D, Prentice IC, Bonnefille R, Ballouche A, Bengo M, Brenac P, Buchet G, Burney D, Cazet J-P, Cheddadi R: Biome reconstruction from pollen and plant macrofossil data for Africa and the Arabian peninsula at 0 and 6000 years. J Biogeogr. 1998, 25: 1007-1027. 10.1046/j.1365-2699.1998.00238.x. View Article Google Scholar Griffith FL: The Petrie Papyri: Hieratic Papyri from Kahun and Gurob (Principally of the Middle Kingdom). (Text + Plates). 1898, London: Bernard Quaritch Google Scholar Ebbell B: The papyrus Ebers. The greatest Egyptian medical document.

1937, Copenhagen: Levin & Munksgaard Google Scholar Kea RA: Expansions and contractions: world-historical change and the Western Sudan world system (1200/1000 B.C.-1200/1250 A.D.). J World Syst Res. 2004, 10: 723-816. View Article Google Scholar Williams BI: African trypanosomiasis. The Wellcome Trust Illustrated History of Tropical Diseases. Edited by: Cox FEG. 1996, London: The Wellcome Trust, 178-191. Google Scholar Cox FEG: History of sleeping sickness (African trypanosomiasis). Infect Dis Clin N Am. 2004, 18: 231-245. 10.1016/j.idc.2004.01.004. View Article Google Scholar Bruce D: Preliminary report on the tsetse fly disease or nagana in Zululand.

1895, Durban: Bennett and Davis Google Scholar Forde RM: Some clinical notes on a European patient in whose blood a trypanosome was observed. J Trop Med. 1902, 5: 261-263. Google Scholar Dutton JE: Preliminary note upon a trypanosome occurring in the blood of man. Thompson Yates Lab Rep. 1902, 4: 455-468. Google Scholar Castellani A: On the discovery of a species of Trypanosoma in the cerebro-spinal fluid of cases of sleeping sickness. Proc R Soc Lond. 1903, 71: 501-508. View Article Google Scholar de Raadt P: The history of sleeping sickness. 2005, World Health Org, [ ] Google Scholar Kleine FK: Weitere wissenschaftliche Beobachtungen über die Entwicklung von Trypanosomen in Glossinen. Dtsch Med Wochenschr. 1909, 35: 924-925. 10.1055/s-0029-1201481.

View Article Google Scholar Broden A: Les infections à trypanosomes au Congo chez l'homme et les animaux (communication préliminaire). Bull Soc d'Etudes Colon. 1904, 11: 116-139. Google Scholar Ziemann H: Beitrag zur Trypanosomenfrage. Zentralbl Bakteriol Parasitenk Infektionskrankh, Abt I, Orig. 1905, 38: 307-314. Google Scholar Stephens JWW, Fantham HB: On the peculiar morphology of a trypanosome from a case of sleeping sickness and the possibility of its being a new species (T. rhodesiense). Proc R Soc Lond B. 1910, 83: 28-33. 10.1098/rspb.1910.0064. View Article Google Scholar Hide G: History of sleeping sickness in East Africa. Clin Microbiol Rev. 1999, 12: 112-125. PubMed Central PubMed Google Scholar Vickerman K: Landmarks in trypanosome research.

Trypanosomiasis and Leishmaniasis. Biology and Control. Edited by: Hide G, Mottram JC, Coombs GH, Holmes PH. 1997, Wallingford, Oxon: Cab International, 1-37. Google Scholar WHO/CDS/CSR/ISR/2000.1: Chapter 8 – African trypanosomiasis. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases. 2000, World Health Organization, 95-106. Google Scholar Bray PG, Barrett MP, Ward SA, de Koning HP: Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol. 2003, 19: 232-239. 10.1016/S1471-4922(03)00069-2. View Article PubMed Google Scholar Kinabo LD: Pharmacology of existing drugs for animal trypanosomiasis. Acta Trop. 1993, 54: 169-83.

10.1016/0001-706X(93)90091-O. View Article PubMed Google Scholar Lyons M: The colonial disease: a social history of sleeping sickness in northern Zaire, 1900–1940. 1992, Cambridge: Cambridge University Press View Article Google Scholar Meyskens FL, Gerner EW: Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res. 1999, 5: 945-951. PubMed Google Scholar Stich A, Steverding D: Trypanosomen – Die Rückkehr einer Seuche. Biol in unserer Zeit. 2002, 32: 294-302. 10.1002/1521-415X(200209)32:5<294::AID-BIUZ294>3.0.CO;2-G. View Article Google Scholar WHO: Human African trypanosomiasis (sleeping sickness): epidemiological update. Weekly Epidemiol Rec.

2006, 81 (8): 71-80. Google Scholar Kabayo JP: Aiming to eliminate tsetse from Africa. Trends Parasitol. 2002, 18: 473-475. 10.1016/S1471-4922(02)02371-1. View Article PubMed Google Scholar Vreysen MJ, Saleh KM, Ali MY, Abdulla AM, Zhu ZR, Juma KG, Dyck VA, Msangi AR, Mkonyi PA, Feldmann HU: Glossina austeni (Diptera: Glossinidae) eradicated on the island of Unguja, Zanzibar, using the sterile insect technique. J Econ Entomol. 2000, 93: 123-135. 10.1603/0022-0493-93.1.123. View Article PubMed Google Scholar Bhalla N: Pan African group takes lead against the tsetse fly. Lancet.

2002, 359: 686-10.1016/S0140-6736(02)07843-1. View Article PubMed Google Scholar Immtech Pharmaceuticals: Immtech completes enrolment in phase III pivotal trial of pafuramidine for African sleeping sickness. Immtech. 2007, [ ] Google Scholar Delespaux V, de Koning HP: Drugs and drug resistance in African trypanosomiasis. Drug Resist Updat. 2007, 10: 30-50. 10.1016/j.drup.2007.02.004. View Article PubMed Google Scholar Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, Checchi F, Ghabri S, Piola P: Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials.

2006, 1: e39-10.1371/journal.pctr.0010039. PubMed Central View Article PubMed Google Scholar Bisser S, N'Siesi FX, Lejon V, Preux PM, Van Nieuwenhove S, Miaka Mia Bilenge C, Büscher P: Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis. 2007, 195: 322-329. 10.1086/510534. View Article PubMed Google Scholar Steverding D: A new initiative for the development of new diagnostic tests for human African trypanosomiasis. Kinetoplastid Biol Dis. 2006, 5: 1-10.1186/1475-9292-5-1. PubMed Central View Article PubMed Google Scholar Copyright © Steverding; licensee BioMed Central Ltd.

2008 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. WHO | Trypanosomiasis, human African (sleeping sickness) Trypanosomiasis, human African (sleeping sickness) Updated February 2016 Key facts Sleeping sickness occurs in 36 sub-Saharan Africa countries where there are tsetse flies that transmit the disease. The people most exposed to the tsetse fly and therefore the disease live in rural areas and depend on agriculture, fishing, animal husbandry or hunting. Human African trypanosomiasis takes 2 forms, depending on the parasite involved: Trypanosoma brucei gambiense accounts for more than 98% of reported cases. Sustained control efforts have reduced the number of new cases. In 2009 the number reported dropped below 10 000 for the first time in 50 years, and in 2014 there were 3796 cases recorded.

Diagnosis and treatment of the disease is complex and requires specifically skilled staff. Definition of the disease Human African trypanosomiasis, also known as sleeping sickness, is a vector-borne parasitic disease. It is caused by infection with protozoan parasites belonging to the genus Trypanosoma. They are transmitted to humans by tsetse fly (Glossina genus) bites which have acquired their infection from human beings or from animals harbouring human pathogenic parasites. Tsetse flies are found just in sub-Saharan Africa though only certain species transmit the disease. For reasons that are so far unexplained, in many regions where tsetse flies are found, sleeping sickness is not. Rural populations living in regions where transmission occurs and which depend on agriculture, fishing, animal husbandry or hunting are the most exposed to the tsetse fly and therefore to the disease. The disease develops in areas ranging from a single village to an entire region. Within an infected area, the intensity of the disease can vary from one village to the next.

Forms of human African trypanosomiasis Human African trypanosomiasis takes 2 forms, depending on the parasite involved: Trypanosoma brucei gambiense is found in 24 countries in west and central Africa. This form currently accounts for over 98% of reported cases of sleeping sickness and causes a chronic infection. A person can be infected for months or even years without major signs or symptoms of the disease. When more evident symptoms emerge, the patient is often already in an advanced disease stage where the central nervous system is affected. Trypanosoma brucei rhodesiense is found in 13 countries in eastern and southern Africa. Nowadays, this form represents under 2% of reported cases and causes an acute infection. First signs and symptoms are observed a few months or weeks after infection. The disease develops rapidly and invades the central nervous system. Only Uganda presents both forms of the disease, but in separate zones. Another form of trypanosomiasis occurs mainly in Latin America. It is known as American trypanosomiasis or Chagas disease. The causal organism belongs to a different Trypanosoma subgenus and is transmitted by a different vector.

Animal trypanosomiasis Other parasite species and sub-species of the Trypanosoma genus are pathogenic to animals and cause animal trypanosomiasis in wild and domestic animals. In cattle the disease is called Nagana. Trypanosomiasis in domestic animals, particularly in cattle, is a major obstacle to the economic development of affected rural areas. Animals can host the human pathogen parasites, especially T.b. rhodesiense, of which domestic and wild animals are an important reservoir. Animals can also be infected with T.b. gambiense and act as a reservoir to a lesser extent. However the precise epidemiological role of the animal reservoir in the gambiense form of the disease is not yet well known. Major human epidemics There have been several epidemics in Africa over the last century: one between 1896 and 1906, mostly in Uganda and the Congo Basin; one in 1920 in a number of African countries; and the most recent epidemic started in 1970 and lasted until the late 1990s.

The 1920 epidemic was controlled thanks to mobile teams which carried out the screening of millions of people at risk. By the mid-1960s, the disease was under control with less than 5000 cases reported in the whole continent. After this success, surveillance was relaxed, and the disease reappeared, reaching epidemic proportions in several regions by 1970. The efforts of WHO, national control programmes, bilateral cooperation and nongovernmental organizations (NGOs) during the 1990s and early 21st century reversed the curve. Since the number of new human African trypanosomiasis cases reported between 2000 and 2012 dropped by 73%, the WHO neglected tropical diseases roadmap targeted its elimination as a public health problem by 2020. Disease burden Sleeping sickness threatens millions of people in 36 countries in sub-Saharan Africa. Many of the affected populations live in remote rural areas with limited access to adequate health services, which complicates the surveillance and therefore the diagnosis and treatment of cases. In addition, displacement of populations, war and poverty are important factors that facilitate transmission.

In 1998, almost 40 000 cases were reported, but estimates were that 300 000 cases were undiagnosed and therefore untreated. During the most recent epidemic the prevalence reached 50% in several villages in Angola, the Democratic Republic of the Congo, and South Sudan. Sleeping sickness was the first or second greatest cause of mortality in those communities, even ahead of HIV/AIDS. In 2009, after continued control efforts, the number of cases reported dropped below 10 000 (9878) for the first time in 50 years. This decline in number of cases has continued with 3796 new cases reported in 2014, the lowest level since the start of systematic global data-collection 75 years ago. The estimated number of actual cases is below 20 000 and the estimated population at risk is 65 million people. Current disease distribution The disease incidence differs from one country to another as well as in different parts of a single country. In the last 10 years, over 70% of reported cases occurred in the Democratic Republic of the Congo (DRC).

The DRC is the only country that currently reports more than 1000 new cases annually and accounts for 85% of the cases reported in 2014. Central African Republic is the only country that declared between 100 and 200 new cases in 2014. Countries such as Angola, Burkina Faso, Cameroon, Chad, Congo, Côte d'Ivoire, Gabon, Guinea, Malawi, South Sudan, Uganda, United Republic of Tanzania, Zambia and Zimbabwe are reporting fewer than 100 new cases per year. Countries like Benin, Botswana, Burundi, Equatorial Guinea, Ethiopia, Gambia, Ghana, Guinea Bissau, Kenya, Liberia, Mali, Mozambique, Namibia, Niger, Nigeria, Rwanda, Senegal, Sierra Leone, Swaziland and Togo have not reported any new cases for over a decade. Transmission of the disease seems to have stopped in some of these countries but there are still some areas where it is difficult to assess the exact situation because the unstable social circumstances and/or difficult accessibility hinder surveillance and diagnostic activities.

Infection and symptoms The disease is mostly transmitted through the bite of an infected tsetse fly but there are other ways in which people are infected: Mother-to-child infection: the trypanosome can cross the placenta and infect the fetus. Mechanical transmission through other blood-sucking insects is possible, however, it is difficult to assess its epidemiological impact. Accidental infections have occurred in laboratories due to pricks with contaminated needles. Transmission of the parasite through sexual contact has been documented. In the first stage, the trypanosomes multiply in subcutaneous tissues, blood and lymph. This is also called haemo-lymphatic stage, which entails bouts of fever, headaches, joint pains and itching In the second stage the parasites cross the blood-brain barrier to infect the central nervous system. This is known as the neurological or meningo-encephalic stage. In general this is when more obvious signs and symptoms of the disease appear: changes of behaviour, confusion, sensory disturbances and poor coordination. Disturbance of the sleep cycle, which gives the disease its name, is an important feature. Without treatment, sleeping sickness is considered fatal although cases of healthy carriers have been reported.

Disease management: diagnosis Disease management is made in 3 steps: Screening for potential infection. This involves using serological tests (only available for T.b.gambiense) and checking for clinical signs - especially swollen cervical lymph nodes. Diagnosing by establishing whether the parasite is present in body fluids. Staging to determine the state of disease progression. This entails examining the cerebrospinal fluid obtained by lumbar puncture. Diagnosis must be made as early as possible to avoid progressing to the neurological stage in order to elude complicated and risky treatment procedures The long, relatively asymptomatic first stage of T. b. gambiense sleeping sickness is one of the reasons why an exhaustive, active screening of the population at risk is recommended, in order to identify patients at an early stage and reduce transmission by removing their status of reservoir. Exhaustive screening requires a major investment in human and material resources. In Africa such resources are often scarce, particularly in remote areas where the disease is mostly found. As a result, some infected individuals may die before they can ever be diagnosed and treated. Treatment The type of treatment depends on the disease stage. The drugs used in the first stage are safer and easier to administer than those for second stage.

Also, the earlier the disease is identified, the better the prospect of a cure. The assessment of treatment outcome requires follow up of the patient up to 24 months and entails laboratory exams of body fluids including cerebrospinal fluid obtained by lumbar puncture, as parasites may remain viable for long periods and reproduce the disease months after treatment. Treatment success in the second stage depends on drugs that cross the blood-brain barrier to reach the parasite. Such drugs are toxic and complicated to administer. In total five different drugs are used for the treatment of sleeping sickness. These drugs are donated to WHO by manufacturers and distributed free of charge to disease endemic countries. Drugs used in first stage treatment: Pentamidine: discovered in 1940, used for the treatment of the first stage of T.b. gambiense sleeping sickness. Despite non-negligible undesirable effects, it is in general well tolerated by patients. Suramin:: discovered in 1920, used for the treatment of the first stage of T.b. rhodesiense. It provokes certain undesirable effects, including urinary tract and allergic reactions.

Drugs used in second stage treatment: Melarsoprol: discovered in 1949, it is used for the treatment of both gambiense and rhodesiense infections. It is derived from arsenic and has many undesirable side effects, the most dramatic of which is reactive encephalopathy (encephalopathic syndrome) which can be fatal (3% to 10%). An increase in resistance to the drug has been observed in several foci, particularly in central Africa. It is currently recommended as first-line treatment for the rhodesiense form, and as second-line for the gambiense form. Eflornithine: this molecule, less toxic than melarsoprol, was registered in 1990. It is only effective against T.b. gambiense. The regimen is complex and difficult to apply. Nifurtimox: A combination treatment of nifurtimox and eflornithine was introduced in 2009. It simplifies the use of eflornithine by reducing the duration of treatment and the number of IV perfusions, but unfortunately it has not been studied for T.b. rhodesiense.

Nifurtimox is registered for the treatment of American trypanosomiasis but not for human African trypanosomiasis. Nevertheless, after safety and efficacy data provided by clinical trials, its use in combination with eflornithine has been included in the "WHO List of Essential Medicines" and is currently recommended as first-line treatment for the gambiense form. Both drugs are provided free of charge by WHO to endemic countries with a kit containing all the material needed for its administration. Public private partnership In 2000 and 2001, WHO established public-private partnerships with Aventis Pharma (now Sanofi) and Bayer HealthCare which enabled the creation of a WHO-led control and surveillance programme, providing support to endemic countries in their control activities and the supply of medicines free of charge. The partnership was renewed in 2006, 2011 and 2016. The success in curbing the number of sleeping sickness cases has encouraged other private partners to sustain the WHO’s initiative towards eliminating the disease as a public health problem. WHO response WHO provides support and technical assistance to national control programmes.

WHO provides the anti-trypanosome medicines free of charge to endemic countries through public-private partnerships with Sanofi (pentamidine, melarsoprol and eflornithine) and with Bayer HealthCare (suramin and nifurtimox). The conditioning and shipment of medicines is done in collaboration with MSF-Logistics. In 2009, WHO set up a biological specimens bank that is available to researchers to facilitate the development of new and affordable diagnostic tools. The bank contains samples of blood, serum, cerebrospinal fluid, saliva and urine from patients infected with both forms of the disease as well as samples from uninfected people from areas where the disease is endemic. In 2014 a coordination network for human African trypanosomiasis was established under WHO leadership to ensure strengthened and sustained efforts to eliminate the disease. The stakeholders include national sleeping sickness control programmes, groups developing new tools to fight the disease, international and non-governmental organizations, and donors.

The objectives of the WHO programme are to: strengthen and coordinate control measures and ensure field activities are sustained; strengthen surveillance systems; ensure accessibility to the diagnosis and the best treatment available; support the monitoring of treatment and drug resistance; develop an information database for epidemiological analysis, including the atlas of the human African trypanosomiasis, completed in collaboration with the Food and Agriculture Organization (FAO); ensure skilled staff by offering training activities; support operational research to improve diagnostic and treatment tools; promote collaboration with the FAO in charge of animal trypanosomiasis and the International Atomic Energy Agency (IAEA) dealing with vector control through male flies made sterile by radiation. The 3 UN agencies along with the African Union have promoted the Programme Against African Trypanosomiasis (PAAT); synergize vector and disease control activities in collaboration with the Pan African Tsetste and Trypanosomosis Eradication Campaign (PATTEC) of the African Union. For more information contact:

Question: 'Economo's Disease', or 'Trypanosomiasis' is better known as what?
Answer: 'SLEEPING SICKNESS'